Results
1 -
10 of
25Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol, Cancer Chemotherapy and Pharmacology Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma, Investigational New Drugs Chemotherapeutic approaches to brain tumors, Cancer Chemotherapy and Pharmacology Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG), Cancer Chemotherapy and Pharmacology Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG), Cancer Chemotherapy and Pharmacology Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas, Journal of Neuro-Oncology Sites and Extents of Alkylation in Tumour Cell DNA and their Relation to Antitumour Effects of Dibromodulcitol and Dianhydrogalactitol, Cancer Chemotherapy and Selective Drug Development Combined treatment of anaplastic astrocytoma (grade 3u20134) with diacetyl-dianhydro-galactitol (DADAG), Journal of Neuro-Oncology Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma, Journal of Neuro-Oncology Chemosensitivity Testing of Human Brain Tumours in Vitro, Modern Neurosurgery 1